Mr. Engel has been founding and building life sciences companies in China since 1990, including NPO Pharmaceuticals (successful exit); Excel PharmaStudies (successful exit); Tiger Medical Group (successful exit); and Haoyisheng (IPO ready). Mr. Engel also has a family fund investing in China-centric healthcare organizations.
Dr. Mya Thandar
Chief Research Scientist
Ph.D in Microbiology. Mya has more than 7 years of experience in phage lysin and lysin-derived antimicrobial peptide (AMP) research. She has characterized and developed first-ever lysins against Cutibacterium acnes and a lysin-derived AMP against Acinetobacter baumannii infections. She is a key architect of LysiThru system, a high-throughput screening platform to efficiently discover and engineer effective lysins against pathogenic bacteria. She graduated from The Rockefeller University, New York, USA.
Dermatologist. China Medical University graduate, majored in Medicine, certified by American ECFMG, and specialized in Dermatology. Trained and worked at the Dermatology Departments of China Medical University and Guangdong Medical University. Dr. Li was a visiting scholar at the Dermatology Department of Asian University in South Korea and a post-doc research fellow at the Dermatology Department of Boston University, with several publications in peer-reviewed Journals. Nearly 30 years’ working experience in the area of Dermatology Clinic, Research, as well as Medical and Clinical functions at Fortune 500 MNCs.
Dr. Assaf Raz
Vice President of R & D in China & Director of Wuhan Laboratory
Ph.D in Biology from Rockefeller University and Leading Global Lysin Expert